FDA Allows Use of J&J’s Ketamine-Derived Nasal Spray Depression Treatment
The U.S. Food and Drug Administration (FDA) has expanded its approval for Johnson & Johnson's nasal spray, Spravato, allowing it to be used as a standalone treatment for millions of U.S. patients dealing with severe depression. The ketamine-derived drug was first approved for use in combination with antidepressants in 2019 and was later used for […]